- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02263131
Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children
Randomized, Double Blind, Active-controlled, Phase Ⅲ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to < 18 Years.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a multi-center, randomized, double-blind, active-controlled study.
Before initiation of any protocol-specific activities, written informed consent was obtained from each patient and their legally acceptable representatives (consent of the legally acceptable representative was required for children younger than 10 years of age, and for the some sites, for children younger than 7 years of age). Subjects who met all of the eligibility criteria after screening assessments as specified in the protocol, were randomized into the test group or the comparator group in a ratio of 5 to 1 according to the pre-generated site-specific randomization table, and received a single dose or two doses of the study vaccine. The investigator performed the efficacy (immunogenicity) and safety assessments throughout the study. Efficacy data were collected at Visit 1 (prior to vaccination) and at the end-of-study visit for efficacy (immunogenicity) assessments, and for safety assessment, subjects and their legally acceptable representatives were instructed to record any treatment-emergent adverse event in Patient Diary cards.
For all randomized subjects, blood sample was obtained prior to vaccination, and the study vaccine 0.5mL or 0.25mL was administered to the deltoid muscle or anterolateral thigh muscle. For children aged from 6 months to <9 years of age who had not been previously exposed to influenza virus or had not previously received influenza vaccine, another dose of the study vaccine was administered 4 to 5 weeks after the first dose. Blood samples were collected 4 to 5 weeks after the last dose of the study drug for the assessment of antibody titer. All subjects were followed for 6 months after the last dose of the study drug for the safety assessments, and Month 6 follow-up visit was the end-of-study visit.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy men or women aged from 6 months to < 18 years
- Subjects were born after full term pregnancy (37 weeks)
- Voluntary written informed consent was obtained from the subject and the subject's legally acceptable representative (consent of legally acceptable representative was required for subjects younger than 10 years of age (and for subjects younger than 7 years of age for the some institutions)).
Exclusion Criteria:
- Subject with a known allergy to eggs, chicken, neomycin, gentamicin or any components of the study vaccine
- Subject who had received an influenza vaccine within the last 6 months
- Subject who has, or has a family history of, an immune system disorder including immune deficiency disease
- Subject with a history of Guillain-Barre syndrome
- Subject with Down's syndrome or cytogenetic disorders.
- Subject with severe chronic disease which in the investigator's opinion would not make the subject a good candidate for the clinical trial
- Subject with hemophilia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection
- Subject who had an acute fever with body temperature > 38.0 Cº within 72 hours prior to administration of the study vaccine
- Subject who had previously received another vaccine within 28 days before administration of the study drug, or is scheduled to receive another vaccine during the study period.
- Subject who had received immunosuppressant or immune modifying drug within the last 3 months prior to administration of the study vaccine
- Subject who had previously received immunoglobulin or blood-derived products within the last 3 months prior to administration of the study vaccine, or is expecting to be treated with immunoglobulin or blood-derived products during the study.
- Subject who had participated in another experimental study within 30 days prior to administration of the study vaccine
- Subject with other clinically significant medical or psychological condition who in the investigator's opinion would not be suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IL-YANG PFS
IL-YANG FLU Vaccine Prefilled Syringe INJ.
|
IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
|
Active Comparator: TIV PFS
VAXIGRIP Prefilled Syringe INJ.
|
VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroconversion
Time Frame: up to Day28(+7)
|
Seroconversion is defined as follows.
(Case 1) A pre-vaccination (Day 0) HI antibody titer < 1:10 and a post-vaccination (Day 28) HI antibody titer ≥ 1: 40.
or (Case 2) a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (Day 28) HI antibody titer.
|
up to Day28(+7)
|
Percentage of Subjects Achieving Seroconversion for HI Antibody After Administration of the Study Vaccine Depending of the Number of Vaccination
Time Frame: up to Day28(+7)
|
Seroconversion: a pre-vaccination (Day 0) hemagglutination-inhibition (HI) antibody titer < 1:10 and a post-vaccination (last vaccination + Day 28) HI antibody titer ≥ 1: 40 (Case 1), or a pre-vaccination (Day 0) HI antibody titer ≥ 1:10 and a minimum four-fold rise in post-vaccination (last vaccination + Day 28) HI antibody titer (Case 2),
|
up to Day28(+7)
|
Seroprotection Rate for HI Antibody
Time Frame: up to Day28(+7)
|
Percentage of Participants With Healthy Children Aged From 6 Months to <18 Years With Seroprotection
|
up to Day28(+7)
|
Seroprotection Rate of HI Antibody
Time Frame: up to Day28(+7)
|
Percentage of subjects achieving seroprotection for HI antibody after administration of the study vaccine depending of the number of vaccination
|
up to Day28(+7)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric Mean Titer* (GMT) of HI Antibody
Time Frame: Day28(+7)
|
Geometric Mean Titer (GMT), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.
|
Day28(+7)
|
GMR of HI Antibody Titer Before Vaccination and After Vaccination
Time Frame: Day28(+7)
|
Geometric Mean Ratio (GMR), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer.
|
Day28(+7)
|
Number of Subjects With a Pre-vaccination (Day 0) HI Antibody Titer < 1:40, Minimum Four-fold Rise in Post-vaccination (Day 28) HI Antibody Titer
Time Frame: Day28(+7)
|
Day28(+7)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jin-Han Kang, MD.PhD, Seoul St. Mary's Hospital, The Catholic University of Korea
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IY_IFEZ_CH_301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on IL-YANG FLU Vaccine Prefilled Syringe INJ.
-
Il-Yang Pharm. Co., Ltd.Completed
-
Il-Yang Pharm. Co., Ltd.Completed
-
Il-Yang Pharm. Co., Ltd.Not yet recruiting
-
Il-Yang Pharm. Co., Ltd.Completed
-
Il-Yang Pharm. Co., Ltd.CompletedInfluenza, HumanKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.CompletedHealthyKorea, Republic of
-
Il-Yang Pharm. Co., Ltd.Completed
-
Boryung Pharmaceutical Co., LtdCompletedPertussis | Tetanus | Diphtheria | PoliomyelitisThailand, Korea, Republic of
-
Green Cross CorporationCompletedInfluenzaKorea, Republic of
-
Green Cross CorporationCompleted